StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ultragenyx Pharmaceutical cash

Cash and short-term investments held at the end of each period.

Ultragenyx Pharmaceutical's cash was $292.00M at Jun 30, 2026. For fiscal 2025 it was $680.00M, up 11.5% from the year before. Over ten years it grew 4.5% a year on average. The highest annual figure on record is $1.20B in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$680.00M+11.5%
FY2024Dec 31, 2024$610.00M+5.6%
FY2023Dec 31, 2023$577.63M-22.8%
FY2022Dec 31, 2022$747.76M+1.0%
FY2021Dec 31, 2021$740.20M-38.4%
FY2020Dec 31, 2020$1.20B+59.1%
FY2019Dec 31, 2019$755.23M+64.3%
FY2018Dec 31, 2018$459.71M+96.0%
FY2017Dec 31, 2017$234.49M-38.3%
FY2016Dec 31, 2016$380.15M-13.0%
FY2015Dec 31, 2015$437.00M+133.1%
FY2014Dec 31, 2014$187.49M+251.3%
FY2013Dec 31, 2013$53.38M-38.1%
FY2012Dec 31, 2012$86.19M+709.7%
FY2011Dec 31, 2011$10.65M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$292.00M-40.1%
Q1 FY2026Mar 31, 2026$413.00M-16.5%
Q4 FY2025Dec 31, 2025$680.00M+11.5%
Q3 FY2025Sep 30, 2025$425.25M-31.6%
Q2 FY2025Jun 30, 2025$487.28M-36.2%
Q1 FY2025Mar 31, 2025$494.39M+20.0%
Q4 FY2024Dec 31, 2024$610.00M+5.6%
Q3 FY2024Sep 30, 2024$621.61M+40.6%
Q2 FY2024Jun 30, 2024$763.82M+38.4%
Q1 FY2024Mar 31, 2024$412.08M-34.5%
Q4 FY2023Dec 31, 2023$577.63M-22.8%
Q3 FY2023Sep 30, 2023$442.09M-50.3%
Q2 FY2023Jun 30, 2023$551.98M+1.7%
Q1 FY2023Mar 31, 2023$629.35M+5.2%
Q4 FY2022Dec 31, 2022$747.76M+1.0%
Q3 FY2022Sep 30, 2022$888.68M+20.6%
Q2 FY2022Jun 30, 2022$542.80M-35.8%
Q1 FY2022Mar 31, 2022$598.32M-38.0%
Q4 FY2021Dec 31, 2021$740.20M-38.4%
Q3 FY2021Sep 30, 2021$737.12M-3.7%
Q2 FY2021Jun 30, 2021$845.76M+4.0%
Q1 FY2021Mar 31, 2021$965.41M+45.6%
Q4 FY2020Dec 31, 2020$1.20B+59.1%
Q3 FY2020Sep 30, 2020$765.52M+45.2%
Q2 FY2020Jun 30, 2020$813.42M+31.6%
Q1 FY2020Mar 31, 2020$663.28M-7.3%
Q4 FY2019Dec 31, 2019$755.23M+64.3%
Q3 FY2019Sep 30, 2019$527.06M+4.8%
Q2 FY2019Jun 30, 2019$618.29M+13.0%
Q1 FY2019Mar 31, 2019$715.32M+32.1%
Q4 FY2018Dec 31, 2018$459.71M+96.0%
Q3 FY2018Sep 30, 2018$503.10M+35.6%
Q2 FY2018Jun 30, 2018$547.13M+36.9%
Q1 FY2018Mar 31, 2018$541.35M+27.3%
Q4 FY2017Dec 31, 2017$234.49M-38.3%
Q3 FY2017Sep 30, 2017$371.07M-6.4%
Q2 FY2017Jun 30, 2017$399.65M–
Q1 FY2017Mar 31, 2017$425.19M–
Q4 FY2016Dec 31, 2016$380.15M–
Q3 FY2016Sep 30, 2016$396.43M–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?